CAJ | 학술논문

目的:应用雷米普利治疗2型糖尿病(T2DM)的肾病患者,比较治疗前、后尿足细胞数量的变化,并探讨雷米普利对肾脏的保护机制.方法:选取56例糖尿病肾病(DN)微量白蛋白尿期的患者,随机分为治疗组和对照组.治疗组每日给予雷米普利5 mg,连续服用3个月.应用小鼠抗人肾小球足细胞特异性蛋白(Podocalyxin,PCX)单克隆抗体,采用间接免疫荧光技术检测尿中PCX阳性染色细胞,计数尿足细胞数量.比较治疗前、后两组的尿足细胞数量.结果:雷米普利治疗组的尿足细胞数量较基线明显下降(P<0.05),与对照组相比差异有统计学意义(P<0.05).结论:雷米普利可以减少DN患者的尿足细胞数量,保护肾功能.
목적:응용뢰미보리치료2형당뇨병(T2DM)적신병환자,비교치료전、후뇨족세포수량적변화,병탐토뢰미보리대신장적보호궤제.방법:선취56례당뇨병신병(DN)미량백단백뇨기적환자,수궤분위치료조화대조조.치료조매일급여뢰미보리5 mg,련속복용3개월.응용소서항인신소구족세포특이성단백(Podocalyxin,PCX)단극륭항체,채용간접면역형광기술검측뇨중PCX양성염색세포,계수뇨족세포수량.비교치료전、후량조적뇨족세포수량.결과:뢰미보리치료조적뇨족세포수량교기선명현하강(P<0.05),여대조조상비차이유통계학의의(P<0.05).결론:뢰미보리가이감소DN환자적뇨족세포수량,보호신공능.
Objective:To compare ramipril treatment of type 2 diabetes mellitus(T2DM)patients with nephropathy before and after urine enough to the change of the number of cells and to explore ramipril kidney protection mechanisms. Method:56 patients with diabetic nephropathy (DN)microalbuminuria were randomly divided into treatment group and control group. The treatment group was given daily ramipril 5 mg,taking three consecutive months. Applications mouse anti-human monoclonal antibody podocyte-specific protein(Podocalyxin,PCX),positively stained cells using indirect immunofluorescence to detect urinary PCX,count the number of urinary podocytes. To compare the number of urinary podocytes pre-treatment. Result:The number of urinary podocytes ramipril treatment group compared with the baseline decreased significantly(P<0.05),compared with the control group,there was a significant difference(P<0.05). Conclusion:Ramipril can reduce the number of urinary podocytes DN patients and protect renal function.